PMID- 17401460
OWN - NLM
STAT- MEDLINE
DCOM- 20070417
LR  - 20220316
IS  - 1476-5586 (Electronic)
IS  - 1522-8002 (Print)
IS  - 1476-5586 (Linking)
VI  - 9
IP  - 3
DP  - 2007 Mar
TI  - Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate 
      cancer cell line: a new perspective for an old model.
PG  - 200-6
AB  - Recent studies have established that a significant fraction of prostate cancers 
      harbor a signature gene fusion between the 5' region of androgen-regulated 
      TMPRSS2 and an ETS family transcription factor, most commonly ERG. Studies on the 
      molecular mechanisms and functional consequences of this important chromosomal 
      rearrangement are currently limited to the VCaP cell line derived from a 
      vertebral bone metastasis of a hormone-refractory prostate tumor. Here we report 
      on the NCI-H660 cell line, derived from a metastatic site of an extrapulmonary 
      small cell carcinoma arising from the prostate. NCI-H660 harbors TMPRSS2-ERG 
      fusion with a homozygous intronic deletion between TMPRSS2 and ERG. We 
      demonstrate this by real-time quantitative polymerase chain reaction, a two-stage 
      dual-color interphase fluorescence in situ hybridization (FISH) assay testing for 
      TMPRSS2 and ERG break-aparts, and single-nucleotide polymorphism oligonucleotide 
      arrays. The deletion is consistent with the common intronic deletion found on 
      chromosome 21q22.2-3 in human prostate cancer samples. We demonstrate the 
      physical juxtaposition of TMPRSS2 and ERG on the DNA level by fiber FISH. The 
      androgen receptor-negative NCI-H660 cell line expresses ERG in an 
      androgen-independent fashion. This in vitro model system has the potential to 
      provide important pathobiologic insights into TMPRSS2-ERG fusion prostate cancer.
FAU - Mertz, Kirsten D
AU  - Mertz KD
AD  - Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115-6110, 
      USA.
FAU - Setlur, Sunita R
AU  - Setlur SR
FAU - Dhanasekaran, Saravana M
AU  - Dhanasekaran SM
FAU - Demichelis, Francesca
AU  - Demichelis F
FAU - Perner, Sven
AU  - Perner S
FAU - Tomlins, Scott
AU  - Tomlins S
FAU - Tchinda, Joelle
AU  - Tchinda J
FAU - Laxman, Bharathi
AU  - Laxman B
FAU - Vessella, Robert L
AU  - Vessella RL
FAU - Beroukhim, Rameen
AU  - Beroukhim R
FAU - Lee, Charles
AU  - Lee C
FAU - Chinnaiyan, Arul M
AU  - Chinnaiyan AM
FAU - Rubin, Mark A
AU  - Rubin MA
LA  - eng
GR  - NCI P50 CA69568/CA/NCI NIH HHS/United States
GR  - R01AG21404/AG/NIA NIH HHS/United States
GR  - P50 CA090381/CA/NCI NIH HHS/United States
GR  - NCI P50 CA090381/CA/NCI NIH HHS/United States
GR  - R01 AG021404/AG/NIA NIH HHS/United States
GR  - P50 CA069568/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Neoplasia
JT  - Neoplasia (New York, N.Y.)
JID - 100886622
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (ERG protein, human)
RN  - 0 (Trans-Activators)
RN  - 0 (Transcriptional Regulator ERG)
RN  - EC 3.4.21.- (Serine Endopeptidases)
RN  - EC 3.4.21.- (TMPRSS2 protein, human)
SB  - IM
MH  - Cell Line, Tumor
MH  - DNA-Binding Proteins/*genetics
MH  - *Gene Fusion
MH  - Gene Rearrangement
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Polymorphism, Single Nucleotide
MH  - Prostatic Neoplasms/*genetics
MH  - Serine Endopeptidases/*genetics
MH  - Trans-Activators/*genetics
MH  - Transcriptional Regulator ERG
PMC - PMC1838578
EDAT- 2007/04/03 09:00
MHDA- 2007/04/18 09:00
PMCR- 2007/03/01
CRDT- 2007/04/03 09:00
PHST- 2007/01/04 00:00 [received]
PHST- 2007/01/23 00:00 [revised]
PHST- 2007/01/24 00:00 [accepted]
PHST- 2007/04/03 09:00 [pubmed]
PHST- 2007/04/18 09:00 [medline]
PHST- 2007/04/03 09:00 [entrez]
PHST- 2007/03/01 00:00 [pmc-release]
AID - 07103 [pii]
AID - 10.1593/neo.07103 [doi]
PST - ppublish
SO  - Neoplasia. 2007 Mar;9(3):200-6. doi: 10.1593/neo.07103.